Compounded medication sourcing for telehealth companies

What is actually different about a telehealth model?

Not the volume. The fact that every fact has to be true in more than one place at once.

A single-site clinic asks one question about one state. A telehealth operator asks the same question of every state it accepts patients in, and the answers diverge sharply between states that look alike from the outside. Georgia’s rule prohibits non-patient-specific supply for human office use in those words, and in the same breath excepts outsourcing facilities from that prohibition — so the route closes for a pharmacy and stays open for a 503B. New Jersey bars it for human use, sterile and non-sterile alike, with no such carve-out. Illinois permits it only for non-sterile preparations. North Carolina permits it as a matter of state pharmacy law and then conditions it on compliance with applicable federal law. Texas grants a plain permission as a matter of Texas pharmacy law, and its rules make no reference to section 353a at all, so the state grant does nothing about the federal statute.

Building one process and applying it everywhere is the failure mode this page exists to name.

Which three questions does each state answer?

They are independent, and answering one tells you nothing about the other two.

Does this state let a 503A pharmacy supply non-patient-specific stock? That is a state pharmacy-rule question, and it sits on top of 21 U.S.C. § 353a, which exempts a compounded drug from three federal requirements only where it is "compounded for an identified individual patient based on the receipt of a valid prescription order."

Does your outsourcing facility hold this state’s credential? Section 353b is a federal exemption from federal requirements and preempts no state licensing scheme. In every state whose receiving side we have read from primary sources, a facility registered with FDA as an outsourcing facility must also hold that state’s own credential before it may ship compounded stock in.

Does your model administer or dispense? A partner clinic injecting in the room and a vial mailed to a patient are different regulated acts, and several states cap or condition the second one specifically.

Where does your supplier’s licence actually live?

Not always where an operations team would look for it, which is why supplier diligence at scale goes wrong quietly.

North Carolina registers outsourcing facilities through the Department of Agriculture and Consumer Services; the word "outsourcing" does not appear anywhere in the Board of Pharmacy’s rules. Texas issues the out-of-state licence through the Department of State Health Services, where the outsourcing-facility election is a checkbox on a wholesale distributor application. Louisiana runs it through the Board of Drug and Device Distributors, with a separate Board of Pharmacy controlled-substance licence on top when the product is scheduled.

Checking a board of pharmacy roster in those three and finding nothing is not evidence that no licence is required. It is evidence that the register you searched is not the one that holds the answer. Ask a supplier for the credential by name and by issuing agency, per state you ship into.

Is there a volume below which none of this applies?

No, and New York is the state that says so most clearly.

New York registers nonresident establishments under Educ. Law § 6808-b, which names outsourcing facilities expressly and reaches shipments to authorised prescribers. The regulation at 8 NYCRR 63.8(e) makes the isolated-transaction exception unavailable to nonresident outsourcing facilities, and no threshold for them exists at all. A pilot in one state, a handful of shipments a month, a single partner clinic: none of it lowers the requirement.

This matters for telehealth specifically because the natural way to enter a new state is small. The registration question has to be settled before the first shipment, not after the volume justifies the paperwork.

What limits shipping product to the patient?

Two of the states we have read cap prescriber dispensing directly, and both caps are short enough to rule out a mail-out model built on office stock.

New York’s § 6807(2)(a) exemption for a prescriber dispensing to their own patients runs to a seventy-two hour supply. New Jersey’s physician-dispensing provision at N.J.S.A. 45:9-22.11 works on a seven-day limit, with injectables excepted from it. Neither is a licensing hurdle you clear once; each is a boundary on the act itself.

The compliant construction for most telehealth models is therefore the one section 353a already describes: the pharmacy compounds against a prescription written for a named patient, and the product travels under that prescription. That is a different transaction from office stock, with a different supplier, a different licence and a different label — which is why ordering for patients in another state is worth reading before the operations design is fixed.

What does FDA say to telehealth companies specifically?

More than to any other audience on this site, and it is aimed at how the product is described rather than at how it is made.

FDA maintains guidance addressed to telehealth companies promoting compounded drugs. It sets out conduct the agency identifies as false or misleading, including branding that implies the telehealth company is itself the compounder, describing a compounded drug as a generic version of, or the same as, an approved drug, claiming it has been approved by FDA or evaluated by the agency for safety and effectiveness, asserting clinical equivalence to the approved drug, and claiming it comes from an approved or licensed facility — the agency states plainly that it neither approves nor licenses any such facility.

Two of those are easy to trip while trying to be reassuring. Every one of them applies to your marketing regardless of which pharmacy or facility fills the order, and regardless of whether your supplier’s own copy is clean.

Which findings change your answer, and what to bring

The state layer is where the real variance lives. The state-by-state office-use guide carries each rule verbatim with its citation and last-reviewed date, and 503A pharmacies and 503B outsourcing facilities compared sets out the federal definitions the whole structure rests on. Operators whose menu is decided by a federal doctrine rather than a state rule should also read the page written for weight-management clinics, and the rest are indexed at sourcing by practice type.

Two of those four inputs have pages of their own. What changes as you add a state — the licence, the credential and the rule that move, and the ones that do not — is at multi-state practice ordering. Which of your orders can travel out of the EMR as an ordinary prescription, and which cannot leave that way at all, is at EMR to pharmacy.

When you apply, four answers move fastest: the states you accept patients in today and the ones next on the list; which prescribers hold which state licences; whether each item is administered by a partner site or shipped to the patient; and how prescriptions leave your EMR. If you want that mapped state by state before you commit, you can apply for an account.